# Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)

> **NCT00375609** · PHASE2 · COMPLETED · sponsor: **Portola Pharmaceuticals** · enrollment: 215 (actual)

## Conditions studied

- Thromboembolism

## Interventions

- **DRUG:** Betrixaban
- **DRUG:** Enoxaparin

## Key facts

- **NCT ID:** NCT00375609
- **Lead sponsor:** Portola Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-01
- **Final completion:** 2007-02
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2023-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00375609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00375609, "Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00375609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*